Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.94 USD | +27.43% | +69.60% | +51.52% |
Mar. 28 | North American Morning Briefing : Stocks Set for -2- | DJ |
Mar. 27 | Outlook Therapeutics Shares Rise After BTIG Upgrade | MT |
Financials (USD)
Sales 2024 * | 238K | Sales 2025 * | 11.85M | Capitalization | 202M |
---|---|---|---|---|---|
Net income 2024 * | -72M | Net income 2025 * | -62M | EV / Sales 2024 * | 851 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.1 x |
P/E ratio 2024 * |
-3.58
x | P/E ratio 2025 * |
-5.13
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.16% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | +27.43% | ||
1 week | +76.11% | ||
Current month | +36.68% | ||
1 month | +34.79% | ||
3 months | +29.05% | ||
6 months | +174.86% | ||
Current year | +51.52% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 8 M€ | +9.75% | - | |
0.00% | 142 M€ | +6.18% | - | |
0.00% | 17 M€ | +5.93% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 11.94 | +27.43% | 1,556,224 |
24-03-27 | 9.37 | +7.95% | 1,469,214 |
24-03-26 | 8.68 | +2.00% | 413,743 |
24-03-25 | 8.51 | -1.39% | 835,575 |
24-03-22 | 8.63 | +22.59% | 21,033,281 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.52% | 202M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |